iGEM infrastructure, BioBricks and standard genetic parts

01Overview and value chain

Markers: [EC: open-repository and material-transfer norms | OECD: 1.6 Genomics and bioinformatics | Regulator: EPA (US)]

Standard genetic parts infrastructure is the shared plumbing beneath synthetic biology: the registries that catalogue reusable DNA elements, the repositories that physically distribute them, the synthesis houses that manufacture new sequence, and the biofoundries that assemble and verify constructs at scale. Its distinguishing feature is that the load-bearing pieces are non-profits and public facilities rather than a competitive vendor market. The iGEM Foundation, a non-profit in Cambridge, Massachusetts, runs the annual global competition in which student teams design, build and test projects from standard parts, and its 2024 Grand Jamboree in Paris drew more than 4,500 attendees around over 400 teams — which is simultaneously a teaching programme, a parts registry and the field’s recruitment pipeline. Addgene distributes plasmids, viral vectors and recombinant antibodies as a non-profit repository and absorbs the material-transfer-agreement burden that would otherwise fall on individual laboratories. The commercial layer supplies what the registries cannot: Twist Bioscience’s silicon-based synthesis platform now reaches 7,000 base pairs on sequences with tandem and inverted repeats, extreme GC content and homopolymers up to 30 base pairs. At the far end, national-scale automation has arrived — Shenzhen’s synthetic biology research infrastructure represents roughly 2 billion RMB of planned investment across more than 400 automated instruments.

The key directions of standard parts infrastructure are:

1. Standard Parts Registry and Competition: the catalogue of reusable biological parts together with the annual student competition that populates and stress-tests it, spanning undergraduate, high-school and graduate teams worldwide.
2. Plasmid Repository and Distribution: non-profit physical distribution of plasmids, viral vectors and recombinant antibodies, including the handling of material transfer agreements and, increasingly, systematic sequence verification of what is deposited.
3. High-Fidelity Gene Synthesis: commercial manufacture of new DNA, where the frontier is not length alone but difficulty — repeats, GC extremes and homopolymers that defeat conventional synthesis.
4. Automated Assembly and Validation: biofoundry-scale construction of large constructs with automated design-build-test-learn cycles, and the long-read sequencing workflows that verify assemblies actually match their design.

Sectoral value chain

[Part Design] ──> [DNA Synthesis] ──> [Assembly] ──> [Validation Sequencing]
                                            │
                                    (registry deposit)
                                            │
                                            ▼
[Reuse by Others] <─── [Repository Distribution] <──┘

Value chain levels

Cross-cutting technologies of the sector:

• Long-Read Validation Workflows: cost-effective high-throughput nanopore sequencing with accompanying software, used to confirm that an assembled or edited plasmid matches its intended design.
• Material Transfer Administration: the legal layer a repository absorbs on behalf of depositors and requesters, without which physical sharing of biological parts does not scale.
• Cloud-Controlled Automation: remote design and scheduling against physical automation, so an external user can commission construction without operating the equipment.

02US

The United States holds the non-profit institutions that define the commons — the competition and registry, and the repository — alongside the commercial synthesis and foundry capacity that supplies them.

iGEM registry and competition, Addgene repository, Twist synthesis, Ginkgo foundry automation

• iGEM Foundation: a non-profit based in Cambridge, Massachusetts, running an annual global synthetic biology competition in which undergraduate, high-school and graduate teams design, build, test and present projects using standard parts and molecular biology techniques. Its 2024 Grand Jamboree in Paris drew more than 4,500 attendees from research, industry, startups, investment, policy and media around over 400 teams.
• Addgene: a non-profit scientific materials repository whose offering spans plasmids, viral vectors and recombinant antibodies plus educational resources and data, and which handles material transfer agreements on researchers’ behalf. It has entered a four-year strategic collaboration with Plasmidsaurus under which the sequencing provider handles 95% of sequencing, aimed at scaling plasmid data accuracy, transparency and accessibility while keeping repository operations cost-effective.
• Twist Bioscience and Ginkgo Bioworks: Twist’s silicon-based DNA synthesis platform added an early-access Complex Genes offering extending clonal gene synthesis to 7,000 base pairs and to sequences with short and long repeats including tandem and inverted, high and low GC content, and homopolymers up to 30 base pairs. Ginkgo’s foundry combines gene design, host selection and fermentation conditions in integrated cell engineering, and it is building a high-throughput automated phenotyping platform with EMSL at Pacific Northwest National Laboratory for the Department of Energy’s microbial molecular phenotyping capability.

03CN

China’s contribution is infrastructure at national scale plus a large commercial synthesis base, and both are explicitly organised around automating the design-build-test-learn cycle rather than around cataloguing parts.

Shenzhen synthetic biology facility, cloud laboratory model, GenScript commercial scale

• Shenzhen synthetic biology research infrastructure (SIAT, CAS): a major national science facility in Guangming Science City with roughly 2 billion RMB of planned investment, led by the Shenzhen Institute of Advanced Technology with Shenzhen Second People’s Hospital and BGI Research participating. It is built as a dual “cloud laboratory” for users and “intelligent laboratory” for operators, and moved into Guangming district in September 2022.
• Automation architecture: the facility comprises three interconnected core platforms — design-and-learning, synthesis-and-testing, and user-detection. The synthesis-and-testing platform covers four subsystems (large DNA fragments, phage, bacteria and yeast), with more than 400 automated instruments organised into over 30 automation function islands, executing synthesis, assembly, transformation, activation, testing and redesign under AI-driven control for fast, low-cost, multi-cycle closed-loop operation with remote customisation and cloud design.
• GenScript (commercial parts supply): founded in 2002 with its R&D and production headquarters established in Nanjing in 2004 and listed on the Hong Kong main board in 2015 (HK01548), it operates four platforms spanning CRO, CDMO, cell therapy and industrial synthetic biology products, with legal entities across the US, China, Hong Kong, Japan, Singapore, the Netherlands and Ireland, more than 5,500 employees of whom over 40% hold a doctorate or master’s degree, 180 granted patents and 670 applications, and gene-synthesis-to-plasmid turnaround as fast as five days.

04EU

Europe’s role is methodological: the biofoundries here have concentrated on making automated assembly trustworthy and on consolidating scattered capability into accessible centres.

Edinburgh Genome Foundry validation workflow, nanopore verification, DTU biosolutions consolidation

• Edinburgh Genome Foundry (assembly validation): developed a biofoundry-scale workflow for validating DNA assemblies using cost-effective, high-throughput long-read Oxford Nanopore sequencing, combining a laboratory protocol with software to verify assembled, cloned or edited plasmids within design-build-test-learn cycles.
• Why validation is the bottleneck: the workflow exists because errors enter from three distinct places — the input DNA, the assembly reaction itself, and handling — so an automated foundry that cannot cheaply verify its own output simply produces unverified constructs faster.
• DTU Biosustain and Biosolutions DTU: its case work includes automated high-resolution time-lapse imaging for microbial experiments through the Reshape imaging system, digitalising evolution experiments; institutionally, DTU has established Biosolutions DTU, a centre led by Andreas Worberg, formerly chief commercial officer of DTU Biosustain, to centralise biosolutions research and streamline access to facilities and expertise for companies, authorities and investors.

05Leading companies and research institutes

06Tech stack and innovations

The stack runs from an abstraction — the standardised part — down to the physical infrastructure that makes reuse practical, and its recent movement has been in verification and automation rather than in the standard itself.

1. Standardisation and the Commons:
   • The registry model treats a genetic element as a component with a defined interface, so that a part can be composed rather than rebuilt, and the annual competition both populates the catalogue and tests whether parts behave as documented in others’ hands.
   • The commons depends on legal plumbing as much as biology: a repository that absorbs material transfer agreements is what allows physical sharing to scale beyond bilateral favours between laboratories.
2. Synthesis at the Difficulty Frontier:
   • Silicon-based synthesis now reaches 7,000 base pairs for clonal genes, but the meaningful advance is sequence difficulty — short and long repeats including tandem and inverted, high and low GC content, and homopolymers up to 30 base pairs.
   • These are precisely the sequences that arise in regulatory elements and repeat-containing natural products, so the constraint being lifted is on what biology can be built, not merely on how much.
3. Automated Assembly and Cloud Control:
   • National-scale facilities organise hundreds of automated instruments into function islands executing synthesis, assembly, transformation, activation, testing and redesign under AI-driven control, with the explicit aim of fast, low-cost, multi-cycle closed loops.
   • The cloud-laboratory model separates the user from the equipment: design is submitted remotely and converted into automated experimental instructions, which is what turns a facility into shared infrastructure rather than one institution’s asset.
4. Verification as the Limiting Step:
   • Long-read nanopore workflows with supporting software validate that an assembled, cloned or edited plasmid matches its design, catching errors from input DNA, the assembly reaction and handling alike.
   • Repository-scale sequencing partnerships apply the same logic to distribution — verifying deposited material systematically so that accuracy and transparency scale with volume rather than degrading against it.

07Value chains and production pipelines

Industrial pipeline of a standard-parts construction cycle (open-repository norms, material transfer agreements, EPA oversight of engineered organisms)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Part Design            │ ───> │ 2. DNA Synthesis          │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Validation Sequencing  │ <─── │ 3. Automated Assembly     │
└───────────────────────────┘      └───────────────────────────┘
               │
               ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Repository Deposit     │ ───> │ 6. Distribution & Reuse   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Part Design

A genetic element is specified against a standard so it can be composed with others rather than rebuilt for each project. This is the abstraction the whole field rests on, and the annual student competition is where it is most heavily exercised, with hundreds of teams building from the shared catalogue each year.

Stage 2: DNA Synthesis

The designed sequence is manufactured. Length is no longer the binding constraint at the scales involved here — difficulty is, and platforms now handle clonal genes to 7,000 base pairs including tandem and inverted repeats, GC extremes and homopolymers up to 30 base pairs.

Stage 3: Automated Assembly

Fragments are combined into larger constructs through biofoundry automation. At national-facility scale this means hundreds of instruments arranged into function islands covering large DNA fragments, phage, bacteria and yeast, executing assembly, transformation and activation under centralised control.

Stage 4: Validation Sequencing

Assemblies are checked against design by cost-effective high-throughput long-read sequencing with supporting analysis software. This stage exists because errors arise from the input DNA, the assembly reaction and handling, and an automated foundry without cheap verification only produces unverified material faster.

Stage 5: Repository Deposit

Verified plasmids and vectors are deposited with a repository that handles storage, catalogue quality and material transfer agreements. Systematic sequencing of deposits — through partnerships covering the large majority of a repository’s sequencing volume — is what keeps catalogue accuracy from degrading as deposit volume grows.

Stage 6: Distribution and Reuse

Material is distributed to laboratories worldwide with transfer terms already handled, and derived constructs and new parts return to the commons. This closing loop is the reason the load-bearing institutions are non-profits and public facilities: the value of the infrastructure is in reuse, which a purely proprietary model would restrict.